CR20170309A - Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas - Google Patents

Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas

Info

Publication number: CR20170309A
Authority: CR; Costa Rica
Prior art keywords: inhibitors; pirazinas; cinasas; pirazolo; janus
Prior art date: 2014-12-05

Application number

CR20170309A

Other languages

English (en)

Spanish (es)

Inventor

John E ; Robinson

Tony P ; Tang

Robert Andrew; Rieger

Raj K ; Raheja

Shelley Allen

Erik James Hicken

Katerina; Leftheris

John P ; Fischer

Ronald Jay; Hinklin

Jay Bradford; Fell

Mark Laurence; Boys

John; Gaudino

Christopher F ; Kraser

Laurence E ; Burgess

Jed; Pheneger

Mark J ; Chicarelli

Ellen; Laird

Yoshitaka; Satoh

Brydon L ; Bennett

Original Assignee

Celgene Corp

Array Biopharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-05

Filing date

2015-12-04

Publication date

2018-02-02

2015-12-04 Application filed by Celgene Corp, Array Biopharma Inc filed Critical Celgene Corp

2018-02-02 Publication of CR20170309A publication Critical patent/CR20170309A/es

Links

239000003112 inhibitor Substances 0.000 title abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
102000042838 JAK family Human genes 0.000 abstract 1
102000015617 Janus Kinases Human genes 0.000 abstract 1
108010024121 Janus Kinases Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
208000037765 diseases and disorders Diseases 0.000 abstract 1
208000014951 hematologic disease Diseases 0.000 abstract 1
210000000056 organ Anatomy 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
238000002054 transplantation Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Transplantation (AREA)
Communicable Diseases (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Child & Adolescent Psychology (AREA)

CR20170309A 2014-12-05 2015-12-04 Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas CR20170309A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462088068P	2014-12-05	2014-12-05
PCT/US2015/064062 WO2016090285A1 (en)	2014-12-05	2015-12-04	4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS

Publications (1)

Publication Number	Publication Date
CR20170309A true CR20170309A (es)	2018-02-02

Family

ID=55069089

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR20170309A CR20170309A (es)	2014-12-05	2015-12-04	Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas

Country Status (29)

Country	Link
US (3)	US10189845B2 (pl)
EP (2)	EP3878451A1 (pl)
JP (2)	JP6641373B2 (pl)
KR (1)	KR20170090476A (pl)
CN (1)	CN107278203B (pl)
AU (1)	AU2015357585B2 (pl)
BR (1)	BR112017011798A2 (pl)
CA (1)	CA2969709A1 (pl)
CL (1)	CL2017001422A1 (pl)
CO (1)	CO2017006674A2 (pl)
CR (1)	CR20170309A (pl)
DK (1)	DK3227297T3 (pl)
ES (1)	ES2865483T3 (pl)
HR (1)	HRP20210501T1 (pl)
HU (1)	HUE054371T2 (pl)
IL (1)	IL252656A0 (pl)
MX (1)	MX386316B (pl)
MY (1)	MY191016A (pl)
PH (1)	PH12017501032A1 (pl)
PL (1)	PL3227297T3 (pl)
PT (1)	PT3227297T (pl)
RS (1)	RS61693B1 (pl)
RU (2)	RU2021102805A (pl)
SG (1)	SG11201704542SA (pl)
SI (1)	SI3227297T1 (pl)
TW (1)	TWI725004B (pl)
UA (1)	UA120065C2 (pl)
WO (1)	WO2016090285A1 (pl)
ZA (1)	ZA201704494B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2017156493A1 (en)	2016-03-11	2017-09-14	Denali Therapeutics Inc.	Compounds, compositions, and methods
PL3227297T3 (pl)	2014-12-05	2021-10-25	Array Biopharma, Inc.	4,6 podstawione-pyrazolo[1,5-a]pirazyny jako inhibitory kinaz janusowych
RS60261B1 (sr) *	2016-02-24	2020-06-30	Pfizer	Pirazolo[1,5-a]pirazin-4-il derivativi kao jak-inhibitori
SI3472153T1 (sl)	2016-06-16	2022-01-31	Denali Therapeutics Inc.	Pirimidin-2-ilamino-1H-pirazoli kot zaviralci LRRK2 za uporabo pri zdravljenju nevrodegenerativnih motenj
GB201617758D0 (en) *	2016-10-20	2016-12-07	Almac Discovery Limited	Pharmaceutical compounds
JP6888101B2 (ja) *	2017-01-18	2021-06-16	アレイバイオファーマインコーポレイテッド	ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
WO2018217946A1 (en) *	2017-05-24	2018-11-29	Denali Therapeutics Inc.	Compounds, compositions and methods
EP3668858A1 (en)	2017-08-14	2020-06-24	Pfizer Inc	Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives
JP6997876B2 (ja)	2018-01-18	2022-02-04	アレイバイオファーマインコーポレイテッド	Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
WO2019143977A1 (en)	2018-01-18	2019-07-25	Array Biopharma Inc.	Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143991A1 (en)	2018-01-18	2019-07-25	Array Biopharma Inc.	SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
CA3111984A1 (en)	2018-09-10	2020-03-19	Array Biopharma Inc.	Fused heterocyclic compounds as ret kinase inhibitors
BR112021020339A2 (pt) *	2019-04-12	2021-12-07	Primegene Beijing Co Ltd	Compostos derivados de pirazolopirazina, composição farmacêutica, e uso dos mesmos
IL288024B2 (en)	2019-05-14	2025-12-01	Provention Bio Inc	Methods and compositions for preventing type
CN113150012B (zh) *	2020-01-22	2023-03-24	浙江海正药业股份有限公司	吡唑并[1,5-a]吡嗪类衍生物及其制备方法和用途
WO2021198980A1 (en)	2020-04-04	2021-10-07	Pfizer Inc.	Methods of treating coronavirus disease 2019
US12006366B2 (en)	2020-06-11	2024-06-11	Provention Bio, Inc.	Methods and compositions for preventing type 1 diabetes
MX2023013851A (es)	2021-05-24	2023-12-08	Provention Bio Inc	Metodos para el tratamiento de diabetes tipo 1.
WO2023083200A1 (zh) *	2021-11-12	2023-05-19	南京明德新药研发有限公司	吡唑并环化合物及其应用
WO2024235167A1 (zh) *	2023-05-12	2024-11-21	海南康哲美丽科技有限公司	一种吡唑并吡嗪类化合物及其晶型的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1105378B1 (en)	1998-08-21	2005-03-30	Parker Hughes Institute	Quinazoline derivatives
DE102007032349A1 (de)	2007-07-11	2009-01-15	Bayer Healthcare Ag	Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
AU2010333804B2 (en)	2009-12-23	2015-07-16	Takeda Pharmaceutical Company Limited	Fused heteroaromatic pyrrolidinones as syk inhibitors
EP2526102B1 (en) *	2010-01-22	2017-03-08	Fundación Centro Nacional de Investigaciones Oncológicas Carlos III	Inhibitors of PI3 kinase
UY33213A (es) *	2010-02-18	2011-09-30	Almirall Sa	Derivados de pirazol como inhibidores de jak
US20110241987A1 (en) *	2010-04-01	2011-10-06	Smart Technologies Ulc	Interactive input system and information input method therefor
PH12012502046A1 (en)	2010-04-14	2017-07-26	Array Biopharma Inc	5,7-substituted~imidazo[1,2-c]pyrimidines as inhibitors of jak kinases
AU2012323399A1 (en) *	2011-10-12	2014-05-29	Array Biopharma Inc.	5,7-substituted-imidazo[1,2-c]pyrimidines
PL2831077T3 (pl) *	2012-03-28	2016-10-31		Bicykliczne pochodne pirazynonowe
PL3227297T3 (pl)	2014-12-05	2021-10-25	Array Biopharma, Inc.	4,6 podstawione-pyrazolo[1,5-a]pirazyny jako inhibitory kinaz janusowych

2015
- 2015-12-04 PL PL15819933T patent/PL3227297T3/pl unknown
- 2015-12-04 UA UAA201707008A patent/UA120065C2/uk unknown
- 2015-12-04 RU RU2021102805A patent/RU2021102805A/ru unknown
- 2015-12-04 MX MX2017007284A patent/MX386316B/es unknown
- 2015-12-04 WO PCT/US2015/064062 patent/WO2016090285A1/en not_active Ceased
- 2015-12-04 BR BR112017011798A patent/BR112017011798A2/pt not_active IP Right Cessation
- 2015-12-04 SI SI201531544T patent/SI3227297T1/sl unknown
- 2015-12-04 EP EP21152373.3A patent/EP3878451A1/en not_active Withdrawn
- 2015-12-04 SG SG11201704542SA patent/SG11201704542SA/en unknown
- 2015-12-04 HR HRP20210501TT patent/HRP20210501T1/hr unknown
- 2015-12-04 TW TW104140878A patent/TWI725004B/zh not_active IP Right Cessation
- 2015-12-04 DK DK15819933.1T patent/DK3227297T3/da active
- 2015-12-04 JP JP2017529681A patent/JP6641373B2/ja not_active Expired - Fee Related
- 2015-12-04 CA CA2969709A patent/CA2969709A1/en not_active Abandoned
- 2015-12-04 MY MYPI2017702034A patent/MY191016A/en unknown
- 2015-12-04 PT PT158199331T patent/PT3227297T/pt unknown
- 2015-12-04 US US15/532,937 patent/US10189845B2/en active Active
- 2015-12-04 AU AU2015357585A patent/AU2015357585B2/en not_active Ceased
- 2015-12-04 ES ES15819933T patent/ES2865483T3/es active Active
- 2015-12-04 RU RU2017123387A patent/RU2742938C2/ru active
- 2015-12-04 CR CR20170309A patent/CR20170309A/es unknown
- 2015-12-04 KR KR1020177018122A patent/KR20170090476A/ko not_active Withdrawn
- 2015-12-04 CN CN201580066136.5A patent/CN107278203B/zh not_active Expired - Fee Related
- 2015-12-04 RS RS20210415A patent/RS61693B1/sr unknown
- 2015-12-04 HU HUE15819933A patent/HUE054371T2/hu unknown
- 2015-12-04 EP EP15819933.1A patent/EP3227297B1/en active Active
2017
- 2017-06-02 PH PH12017501032A patent/PH12017501032A1/en unknown
- 2017-06-04 IL IL252656A patent/IL252656A0/en active IP Right Grant
- 2017-06-05 CL CL2017001422A patent/CL2017001422A1/es unknown
- 2017-06-30 CO CONC2017/0006674A patent/CO2017006674A2/es unknown
- 2017-07-03 ZA ZA2017/04494A patent/ZA201704494B/en unknown
2018
- 2018-12-06 US US16/212,493 patent/US10730880B2/en active Active
2019
- 2019-12-11 JP JP2019223760A patent/JP2020055859A/ja active Pending
2020
- 2020-06-02 US US16/890,663 patent/US11028093B2/en active Active

Also Published As

Publication number	Publication date
CO2017006674A2 (es)	2017-10-20
MX386316B (es)	2025-03-18
AU2015357585B2 (en)	2020-07-02
HUE054371T2 (hu)	2021-09-28
JP2018507167A (ja)	2018-03-15
US10730880B2 (en)	2020-08-04
PH12017501032A1 (en)	2017-11-27
TW201632523A (zh)	2016-09-16
MX2017007284A (es)	2017-08-25
TWI725004B (zh)	2021-04-21
US10189845B2 (en)	2019-01-29
RS61693B1 (sr)	2021-05-31
RU2742938C2 (ru)	2021-02-11
PL3227297T3 (pl)	2021-10-25
EP3878451A1 (en)	2021-09-15
EP3227297A1 (en)	2017-10-11
US20200291039A1 (en)	2020-09-17
RU2017123387A3 (pl)	2019-06-03
US20190177328A1 (en)	2019-06-13
RU2017123387A (ru)	2019-01-11
CL2017001422A1 (es)	2018-01-05
DK3227297T3 (da)	2021-04-06
US11028093B2 (en)	2021-06-08
CN107278203A (zh)	2017-10-20
SI3227297T1 (sl)	2021-04-30
JP2020055859A (ja)	2020-04-09
BR112017011798A2 (pt)	2017-12-26
AU2015357585A1 (en)	2017-07-13
CA2969709A1 (en)	2016-06-09
JP6641373B2 (ja)	2020-02-05
CN107278203B (zh)	2020-05-19
KR20170090476A (ko)	2017-08-07
WO2016090285A1 (en)	2016-06-09
PT3227297T (pt)	2021-04-09
HRP20210501T1 (hr)	2021-05-14
EP3227297B1 (en)	2021-01-20
MY191016A (en)	2022-05-28
ES2865483T3 (es)	2021-10-15
UA120065C2 (uk)	2019-09-25
ZA201704494B (en)	2022-03-30
RU2021102805A (ru)	2021-02-12
SG11201704542SA (en)	2017-07-28
IL252656A0 (en)	2017-07-31
US20170362240A1 (en)	2017-12-21

Publication	Publication Date	Title
CR20170309A (es)	2018-02-02	Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas
CO6630187A2 (es)	2013-03-01	5.7-sustituido -imidazol[1.2-c]pirimidinas como inhibidores de cinasas jak
UY34388A (es)	2014-04-30	"5,7-IMIDAZO[1,2-c]PIRIMIDINAS SUSTITUIDAS"
CL2018003060A1 (es)	2018-12-14	Compuestos de pirimidina como inhibidores de la quinasa jak.
CR20150633A (es)	2016-04-05	Derivados del bipirazol como inhibidores jak
CO2017012267A2 (es)	2018-03-28	Compuestos de naftiridina como inhibidores de la quinasa jak
MX2013001970A (es)	2013-08-09	Compuestos de pirrolopirimidina y usos de los mismos.
MX390348B (es)	2025-03-20	Compuestos de benzimidazol como inhibidores de c-kit
CL2017000992A1 (es)	2017-11-17	Compuestos de indol carboxamida utiles como inhibidores de cinasa
SV2018005655A (es)	2018-04-27	"derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer"
MX2017016655A (es)	2018-05-15	Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
MX385082B (es)	2025-03-14	Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
MX372997B (es)	2020-04-06	Compuestos de aminopirimidina como inhibidores de jak.
MX390537B (es)	2025-03-20	Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm
MX2017000806A (es)	2017-05-01	Derivados de 2-h-indazol como inhibidores de kinasas dependientes de ciclinas (cdk) y usos terapeuticos de los mismos.
MX2018012541A (es)	2019-01-17	Inhibidores de bromodominios.
UY35625A (es)	2014-12-31	Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
PE20160689A1 (es)	2016-07-28	Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas
ECSP18026386A (es)	2018-07-31	Sales de un inhibidor de pim quinasa
EA201650003A1 (ru)	2017-03-31	Соединённые циклоалкилом дигетероциклические производные
EA201692371A1 (ru)	2017-04-28	1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений
AR133852A2 (es)	2025-11-05	Sales de un inhibidor de pim quinasa
EA202192822A1 (ru)	2022-02-03	Нафтиридиновые соединения в качестве ингибиторов jak киназы